AV7909
Showing 1 - 12 of 12
Anthrax Trial in United States (AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL))
Not yet recruiting
- Anthrax
- AV7909 Full Dose (0.5 mL)
- AV7909 Half Dose (0.25 mL)
-
Hickory, North Carolina
- +6 more
Aug 10, 2023
Anthrax, Anthrax Immunisation Trial in Baltimore (AV7909)
Not yet recruiting
- Anthrax
- Anthrax Immunisation
- AV7909
-
Baltimore, Maryland
- +1 more
Apr 7, 2022
Anthrax Trial in United States (Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909)
Completed
- Anthrax
- Ciprofloxacin 500Mg Tablet
- +2 more
-
DeLand, Florida
- +3 more
Nov 9, 2021
Tuberculosis Trial in Shanghai (Placebo, Low dose adjuvant, High dose adjuvant)
Completed
- Tuberculosis
- Placebo
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Public Health clinical Center
Mar 9, 2022
Type 2 Diabetes Trial in Worldwide (Tirzepatide, Dulaglutide)
Active, not recruiting
- Type 2 Diabetes Mellitus
-
Birmingham, Alabama
- +646 more
Jan 18, 2023
Cardiovascular Disease Trial in Worldwide (bococizumab (PF-04950615), Placebo)
Terminated
- Cardiovascular Disease
- bococizumab (PF-04950615)
- Placebo
-
Athens, Alabama
- +1595 more
Apr 18, 2019
Cardiovascular Disease Trial in Worldwide (bococizumab (PF-04950615), Placebo)
Terminated
- Cardiovascular Disease
- bococizumab (PF-04950615)
- Placebo
-
Athens, Alabama
- +1745 more
Jun 14, 2018
Bacillus Anthracis (Anthrax) Infection Trial in Miami, Raleigh, Salt Lake City (BioThrax, AV7909 Formulation 1, AV7909
Completed
- Bacillus Anthracis (Anthrax) Infection
- BioThrax
- +5 more
-
Miami, Florida
- +2 more
Aug 1, 2014
Malaria Trial in Washington (MSP1 42-C1/Alhydrogel, CPG 7909)
Completed
- Malaria
- MSP1 42-C1/Alhydrogel
- CPG 7909
-
Washington, District of ColumbiaCenter for Immunization Research, Johns Hopkins University, Bloo
Jan 18, 2008